A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial

BACKGROUND: Aberrant fibroblast growth factor receptor (FGFR) signaling can substantially influence oncogenicity. Despite that FGFR gene abnormality is often detected by cancer genome profiling tests, there is no tumor-agnostic approval yet for these aberrations. E7090 (tasurgratinib) is an orally a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiba, Yohei, Sudo, Kazuki, Kojima, Yuki, Okuma, Hitomi, Kohsaka, Shinji, Machida, Ryunosuke, Ichimura, Masahiko, Anjo, Kenta, Kurishita, Kazumi, Okita, Natsuko, Nakamura, Kenichi, Kinoshita, Ichiro, Takahashi, Masanobu, Matsubara, Junichi, Kusaba, Hitoshi, Yonemori, Kan, Takahashi, Masamichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361602/
https://www.ncbi.nlm.nih.gov/pubmed/35945547
http://dx.doi.org/10.1186/s12885-022-09949-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361602/
https://www.ncbi.nlm.nih.gov/pubmed/35945547
http://dx.doi.org/10.1186/s12885-022-09949-8

Ejemplares similares